Navigation Links
Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
Date:12/5/2007

THE WOODLANDS, Texas, Dec. 5 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that dosing has commenced in a Phase 2a clinical trial with LX6171, an oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia, and vascular dementia. The initial stage of the trial will assess the bioavailability of a new oral-suspension formulation in healthy elderly subjects with a second stage evaluating safety, tolerability and cognitive effects in elderly subjects with age-associated memory impairment (AAMI).

"AAMI is an emerging area of clinical research and offers an expedient population for obtaining proof-of-concept with a drug candidate, like LX6171, that has a broad range of potential applications in the area of cognitive disorders," said Philip M. Brown, M.D., J.D., vice president of clinical development at Lexicon. "Following the strength of the Phase 1 data indicating LX6171 is generally well tolerated, we have adopted a two-stage strategy for Phase 2a in order to transition to our new oral suspension formulation and to assess for improvements in a variety of cognitive dimensions as we enter the elderly population."

Phase 2 Study Design

The initial stage of the trial will assess the bioavailability of a single-dose oral suspension in 16 healthy elderly subjects. The second stage will be a randomized, double-blind, placebo-controlled evaluation of safety, tolerability, and cognitive effects in approximately 120 subjects over four weeks. This stage is anticipated to include three groups of 40 subjects each, exploring two dose levels with a placebo control. Exact dose levels for the second stage wi
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009).... 30 Cytokine PharmaSciences, Inc.... of CPSI-2364, its orally active, small-molecule i...pro-inflammatory cytokines. Results of the safety... volunteers confirm the safety of this compound in... subjects completed the study, including those rec...
(Date:11/30/2009)...PRNewswire/ -- The Simmons law firm,s Trent Miracl...ing thousands of women that were seriously injured...rol pill manufactured and marketed by Bayer Pharma...istrict Litigation has ordered that all federal Ya...idated and centralized for pretrial litigation in ...
(Date:11/30/2009)... 30 According to Millennium Resear...chnology market intelligence, the nearly $1.2 bill...most 5% over 2008 as patients chose to delay or fo... The market will, however, begin recovery in 2010,...ion growth rates of over 15%. MRG,s facial injecta...
Breaking Medicine Technology:Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2Simmons Firm's Partner Trent Miracle Chosen to Help Lead National Litigation Against Bayer 2Facial Injectables Emerge From the Recession 2Facial Injectables Emerge From the Recession 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 1Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 2Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 3Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 4Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 5Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 6Cumberland Pharmaceuticals Launches Caldolor 28R 29 in the United States for Treatment of Pain and Fever 56530 7Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 1Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 2Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 3Hard to Treat Diseases Inc 28HTDS 29 and Landstar Inc 28LDSR 29 Cash Reward 56529 4Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 1Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 2Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 3Prometheus Announces Co Pay Assistance Savings Program for LOTRONEX 28R 29 28alosteron HCl 29 Tablets 56526 4
...MELBOURNE, Australia, Feb. 11 Phosphagenics,Limit...PGNY) and Nestle,Nutrition (Nestle) today announce... establish the efficacy of Phosphagenics, Phospha ...vancing at three sites in Adelaide,Australia., Ba...ants, the,double-blind phase 2 trial, which is ful...
...BOULDER, Colo., and MONTREAL, Feb. 11 ,Pharmion (N...y announced that,the European Medicines Agency (EM...CD0103, a histone deacetylase (HDAC) inhibitor, as...acute myelogenous leukemia in the,European Union (...duct be,intended for the treatment of life-threate...
Other Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:11/30/2009)...avily more often than younger people, study finds,...- Older people who are problem drinkers consume mo...report finds, possibly because they need more alco... a study released this month, people dependent on ... drinks a week, on average. By contrast, younger a...
(Date:11/30/2009).... Rappa, MD, explores the intricate connection bet...ealing Heart to Soul: One Doctor’s Journey o...9). , Dallas, TX (Vocus) ... let go of negative emotions, whether caused by us...oulders. Oftentimes, this disease of the human spi...
(Date:11/30/2009)..., Nov. 30 Baxa Corporation is spon... "culture of safety" means in today,s pharmacy env...eating a Culture of Safety in Pharmacy ," features... their experiences with culture of safety, what it...d the role of technology in enabling or inhibiting...
(Date:11/30/2009)...v. 30 EMD Serono, an affiliate of ...at it received a refuse to file letter from the US...g Application (NDA) for Cladribine Tablets, EMD Se...n of cladribine, as a therapy for relapsing forms ...ll work closely with the FDA to fully understand F...
(Date:11/30/2009)... A new study has found that 27% of...rance customers have a current intention to shop f...he figure is up from 20% in 2008. Over the past f...een a leading indicator of actual switching patter...itch actually will leave their current insurer for...
Breaking Medicine News(10 mins):Health News:Binge Drinking Not Just a Rite of the Young 2Health News:Healing from the Inside Out: Compelling New Book Explores the Intricate Connection between Body, Soul, and Better Health 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 2Health News:Baxa to Sponsor ASHP Midday Symposium: Creating a Culture of Safety in Pharmacy, A Panel Discussion on Lessons Learned 3Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 2Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 3Health News:More Seniors Considering Health Insurance Switch 2
...sparities Show That,"Geography Matters" for U.S. C... Identified as 10 Bottom States by Key Child Well-...ates of,Louisiana and Vermont may be part of the s... is born and raised can,make a shockingly large di...
...ETAIRIE, La., April 2, 2008 OrthoSynetics(TM), th...ntic and dental practices,worldwide, produces tele...s,and practices -- and this year, the production o..., but for the opportunity to work,and contract wit...
...al attention at any,sign of infection, ROCHESTER,...ds that patients who are 50 or older and take mult...y bowel disease have a higher,risk for developing ...or Crohn,s disease, the most common forms of infla...
...tions are associated with increased risk of lung c...eam led by scientists at The University of Texas M... online edition of Nature Genetics. , "This is th... in M. D. Anderson,s Department of Epidemiology. T...
...dents have been indicted in connection with an $11...ion clinics, Assistant Attorney General,Alice S. F.... Alexander,Acosta of the Southern District of Flo...Carmen Gonzalez,33, were all charged today in fede...
...f Upper,Union Street Veterinary Hospital in Schene...mmit VetPharm,s "The Great Vectra 3D(TM)" $125,000...s multi-level contest and,will receive $25,000 in ...m. There will be one more lucky $25,000,winner in ...
Other Medicine News:Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 2Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 3Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 4Health News:Report: 'Life And Death' Differences in U.S. Child Well-Being Exist Between Top and Bottom States, Youths Up to Three Times More Likely to Die Before Adulthood in Some Parts of U.S. 5Health News:OrthoSynetics(TM) Brings Ad Production Home to New Orleans 2Health News:Mayo Clinic Identifies Infection Risks for Patients with Inflammatory Bowel Disease 2Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 2Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 3Health News:Genetic variations raise lung cancer risk for smokers and ex-smokers 4Health News:Seven Miami-Area Residents Charged in $11 Million Medicare Fraud Scheme 2Health News:Summit VetPharm Announces Second Winner in Its 'Great Vectra 3D(TM)' $125,000 Giveaway 2
Satin-Slip® 10FR Intubating Stylet
Disposable Aluminum 11 1/2" Stylette
Solid Copper Malleable Stylette
S5000N Ultra-Slip™ Stylet
Medicine Products: